DeuteRx (DRX-065 Drug) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

DeuteRx (DRX-065 Drug) General Information

Description

A clinical stage drug under development as a therapy for NASH (non-alcoholic steatohepatitis). The patent-protected drug candidate is a mitochondrial pyruvate carrier (MPC) inhibitor that is currently in phase 1 development and has the potential to treat the underlying root causes of non-alcoholic fatty liver disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 300 Brickstone Square
  • Suite 201
  • Andover, MA
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Poxel
Corporate Office
  • 300 Brickstone Square
  • Suite 201
  • Andover, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DeuteRx (DRX-065 Drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DeuteRx (DRX-065 Drug)‘s full profile, request access.

Request a free trial

DeuteRx (DRX-065 Drug) Patents

  • 77

    Total Documents Applications and Grants

  • Total Patents Families

  • 42

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

DeuteRx (DRX-065 Drug) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260085033-A1 Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof Pending 01-May-2024
WO-2025231268-A1 Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof Pending 01-May-2024
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same Active 22-Dec-2017
US-20210340125-A1 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same Active 22-Dec-2017
WO-2019126704-A1 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same Inactive 22-Dec-2017 C07D403/04
To view DeuteRx (DRX-065 Drug)’s complete patent history, request access »

DeuteRx (DRX-065 Drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DeuteRx (DRX-065 Drug)‘s full profile, request access.

Request a free trial

DeuteRx (DRX-065 Drug) FAQs

  • Where is DeuteRx (DRX-065 Drug) headquartered?

    DeuteRx (DRX-065 Drug) is headquartered in Andover, MA.

  • What industry is DeuteRx (DRX-065 Drug) in?

    DeuteRx (DRX-065 Drug)’s primary industry is Buildings and Property.

  • Is DeuteRx (DRX-065 Drug) a private or public company?

    DeuteRx (DRX-065 Drug) is a Private company.

  • What is the current valuation of DeuteRx (DRX-065 Drug)?

    The current valuation of DeuteRx (DRX-065 Drug) is .

  • What is DeuteRx (DRX-065 Drug)’s current revenue?

    The current revenue for DeuteRx (DRX-065 Drug) is .

  • Who are DeuteRx (DRX-065 Drug)’s investors?

    DeuteRx has invested in DeuteRx (DRX-065 Drug).

  • When was DeuteRx (DRX-065 Drug) acquired?

    DeuteRx (DRX-065 Drug) was acquired on 30-Aug-2018.

  • Who acquired DeuteRx (DRX-065 Drug)?

    DeuteRx (DRX-065 Drug) was acquired by Poxel.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process